Sex Age Disease stem cell source Donor HLA mismatch Conditioning ATG relapse/progression aGVHD cGVHD
no reactivation 1 F 47,3 AML PB Unrelated - NMA - - II - IV -
2 M 43,8 AML PB Related - NMA - 6 months II - IV Extensive
3 M 22,6 ALL PB unrelated - MA Yes - none - I Limited
4 M 52,3 NHL PB Related Yes NMA Yes - none - I Limited
low reactivation 5 F 32,1 AML PB Unrelated - MA Yes - none - I -
6 M 28,4 ALL PB Unrelated - NMA Yes - none - I Extensive
7 M 47,9 MM PB Unrelated - NMA Yes 14 months none - I -
8 M 59,3 AML PB Unrelated Yes NMA Yes < 1 month II - IV Extensive
high reactivation 9 M 44,3 AML PB Related - MA - - none - I Extensive
10 M 18,8 NHL PB Unrelated - NMA Yes - none - I -
11 M 57,1 NHL PB Unrelated - NMA Yes - none - I Limited
12 M 51,8 NHL PB Related - NMA - < 1 month II - IV Extensive
Abbreviations: AML: Acute Myeloid Leukemia; ALL: Acute Lymphoid Leukemia; NHL: Non Hodgkin Lymphoma; MM: Multiple Myeloma; PB: Peripheral Blood; NMA: Non-Myeloablative; MA: Myeloablative; ATG: Antithymocyte Globulin; aGVHD: Acute Graft Versus Host Disease; cGVHD: Chronic Graft Versus Host Disease.
Table 1B: Patient characterisitcs retrospective study.